ABBV 838

Drug Profile

ABBV 838

Alternative Names: ABBV-838

Latest Information Update: 03 Mar 2017

Price : $50

At a glance

  • Originator AbbVie
  • Class Antineoplastics; Drug conjugates; Immunoconjugates
  • Mechanism of Action CD319 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Multiple myeloma

Most Recent Events

  • 15 Feb 2017 Phase-I clinical trials in Multiple myeloma (Combination therapy, Second-line therapy or greater) in Australia (IV) (NCT02951117)
  • 28 Oct 2016 AbbVie plans a phase Ib trial for Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA, France, Spain and Australia (IV, Infusion) (NCT02951117)
  • 01 May 2015 Phase-I clinical trials in Multiple myeloma (Second-line therapy or greater) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top